BioCryst Pharmaceuticals Statistics
Total Valuation
BCRX has a market cap or net worth of $2.48 billion. The enterprise value is $2.96 billion.
| Market Cap | 2.48B |
| Enterprise Value | 2.96B |
Important Dates
The last earnings date was Wednesday, August 5, 2026, before market open.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BCRX has 255.54 million shares outstanding. The number of shares has increased by 10.24% in one year.
| Current Share Class | 255.54M |
| Shares Outstanding | 255.54M |
| Shares Change (YoY) | +10.24% |
| Shares Change (QoQ) | +9.46% |
| Owned by Insiders (%) | 0.88% |
| Owned by Institutions (%) | 91.00% |
| Float | 222.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 22.64 |
| PS Ratio | 2.64 |
| Forward PS | 3.58 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 6.64 |
| P/OCF Ratio | 6.59 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.84, with an EV/FCF ratio of 7.94.
| EV / Earnings | n/a |
| EV / Sales | 3.15 |
| EV / EBITDA | 6.84 |
| EV / EBIT | 6.90 |
| EV / FCF | 7.94 |
Financial Position
The company has a current ratio of 2.32
| Current Ratio | 2.32 |
| Quick Ratio | 2.22 |
| Debt / Equity | n/a |
| Debt / EBITDA | 1.92 |
| Debt / FCF | 2.24 |
| Interest Coverage | 5.70 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 52.86% |
| Return on Invested Capital (ROIC) | 138.77% |
| Return on Capital Employed (ROCE) | 122.99% |
| Weighted Average Cost of Capital (WACC) | 7.25% |
| Revenue Per Employee | $2.16M |
| Profits Per Employee | -$884,306 |
| Employee Count | 435 |
| Asset Turnover | 1.85 |
| Inventory Turnover | 38.32 |
Taxes
In the past 12 months, BCRX has paid $3.49 million in taxes.
| Income Tax | 3.49M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +16.73% in the last 52 weeks. The beta is 0.55, so BCRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | +16.73% |
| 50-Day Moving Average | 9.71 |
| 200-Day Moving Average | 8.51 |
| Relative Strength Index (RSI) | 50.07 |
| Average Volume (20 Days) | 3,244,057 |
Short Selling Information
The latest short interest is 32.94 million, so 12.89% of the outstanding shares have been sold short.
| Short Interest | 32.94M |
| Short Previous Month | 32.80M |
| Short % of Shares Out | 12.89% |
| Short % of Float | 14.81% |
| Short Ratio (days to cover) | 9.31 |
Income Statement
In the last 12 months, BCRX had revenue of $940.61 million and -$384.67 million in losses. Loss per share was -$1.68.
| Revenue | 940.61M |
| Gross Profit | 727.92M |
| Operating Income | 429.25M |
| Pretax Income | -381.19M |
| Net Income | -384.67M |
| EBITDA | 433.05M |
| EBIT | 429.25M |
| Loss Per Share | -$1.68 |
Balance Sheet
The company has $352.57 million in cash and $836.65 million in debt, with a net cash position of -$484.07 million or -$1.89 per share.
| Cash & Cash Equivalents | 352.57M |
| Total Debt | 836.65M |
| Net Cash | -484.07M |
| Net Cash Per Share | -$1.89 |
| Equity (Book Value) | -454.29M |
| Book Value Per Share | -1.78 |
| Working Capital | 275.84M |
Cash Flow
In the last 12 months, operating cash flow was $376.14 million and capital expenditures -$2.76 million, giving a free cash flow of $373.38 million.
| Operating Cash Flow | 376.14M |
| Capital Expenditures | -2.76M |
| Depreciation & Amortization | 3.80M |
| Net Borrowing | 127.48M |
| Free Cash Flow | 373.38M |
| FCF Per Share | $1.46 |
Margins
Gross margin is 77.39%, with operating and profit margins of 45.63% and -40.90%.
| Gross Margin | 77.39% |
| Operating Margin | 45.63% |
| Pretax Margin | -40.53% |
| Profit Margin | -40.90% |
| EBITDA Margin | 46.04% |
| EBIT Margin | 45.63% |
| FCF Margin | 39.70% |
Dividends & Yields
BCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.24% |
| Shareholder Yield | -10.24% |
| Earnings Yield | -15.52% |
| FCF Yield | 15.06% |
Analyst Forecast
The average price target for BCRX is $20.82, which is 114.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.82 |
| Price Target Difference | 114.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | -1.45% |
| EPS Growth Forecast (3Y) | 25.51% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BCRX has an Altman Z-Score of 0.52 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.52 |
| Piotroski F-Score | 6 |